FDA Exhibit Panel Risk Disclosure Training | Atlas Primer

The Specific Pain: When Booth Conversations Omit Material Risk Information

Recent FDA OPDP enforcement highlights a persistent commercial compliance failure at medical congresses and trade shows: "The exhibit panel contains claims about the benefits of Soaanz, as discussed above, but fails to include any risk information about the drug. By omitting the risks associated with Soaanz, the exhibit panel fails to provide material information about the consequences that may result from the use of Soaanz and therefore misleadingly represents the drug's risks."

Even when promotional review committees scrutinize physical booth panels, the highest regulatory exposure occurs in live verbal interactions next to those displays. When a prescribing physician walks up to an exhibit booth and asks a rapid question about efficacy or dosing convenience, field representatives instinctively pitch clinical benefits while omitting boxed warnings, contraindications, and material adverse reactions. Under time pressure on a crowded congress floor, reps treat booth conversations as casual networking rather than regulated promotional exchanges that demand complete fair balance.

The Ripple Effect of Omitting Risk Disclosures at Congress Exhibits

A single uncalibrated booth interaction or unbalanced exhibit display can trigger an FDA Untitled Letter or Warning Letter, forcing public corrective messaging and halting commercial momentum for a flagship therapy. Beyond direct regulatory censure, compliance breakdowns at medical conferences erode trust with key opinion leaders, expose executive leadership to rigorous audit scrutiny, and force legal teams to impose restrictive communication freezes across the entire sales force.

Why Traditional Solutions Fail Here

Pharmaceutical compliance teams typically prepare field representatives for medical conferences using static slide decks, regulatory checklists, and multiple-choice e-learning modules. While representatives easily pass written quizzes on fair balance rules, reading a policy document does not build vocal composure when a busy cardiologist interrupts a presentation or challenges a visual panel claim. Static training fails to replicate the acoustic noise, fast pace, and social pressure of a live exhibit booth, leaving commercial reps unprepared to pivot smoothly from benefit claims into mandatory risk disclosures.

The Atlas Primer Solution

Atlas Primer closes the gap between written promotional policies and live conference execution through realistic AI voice simulations. Before stepping onto the exhibit floor, pharmaceutical sales representatives and commercial booth staff rehearse high-pressure physician encounters with responsive AI avatars programmed to test on-label boundaries and interrupt risk transitions.

Capabilities Built for Pharma Commercial Compliance

• Live Congress Booth Fair Balance Rehearsal: Field representatives practice pairing every efficacy statement on an exhibit panel with verbatim material risk and contraindication disclosures during dynamic, multi-turn voice dialogues. The simulator pressures reps with time-constrained physician personas who attempt to skip safety details, building automatic verbal compliance habits.


• Automated Omission Detection and Regulatory Scoring: Every practice conversation is evaluated instantly against approved product labeling and FDA OPDP fair balance standards to flag missing risk statements or overstated efficacy claims. Commercial training directors gain empirical readiness scorecards across the entire congress delegation before the event opens.


• Compliant Medical Science Liaison Handoff Drills: When simulated healthcare providers push past approved exhibit claims into off-label populations or unapproved comparative endpoints, representatives practice halting promotional commentary immediately. Reps rehearse executing a clean, documented referral to a Medical Science Liaison without speculating or misleading the clinician.